Woody Bryan

Woody Bryan, Ph.D., President and CEO of Revolo Biotherapeutics, dives into the innovative realm of peptide therapeutic delivery. He shares his transition to CEO and the bold strategic decision to shift the administration method for peptide candidates targeting allergies and autoimmune diseases. The discussion highlights the evolution of drug delivery methods, focusing on subcutaneous administration and the patient-centric approach. Bryan also outlines the importance of collaboration, early research data, and the upcoming clinical trials set to redefine their therapeutic landscape.